Stem Cell Research: Ethical Issues

July 19, 2006

Judith A. Johnson
Specialist in Life Sciences
Domestic Social Policy Division

Erin D. Williams
Specialist in Bioethical Policy
Domestic Social Policy Division
Summary

The central question before Congress in the debate over stem cell research is how to treat embryonic stem cell research (ESR), which may lead to lifesaving treatments, but which requires the destruction of embryos. The current federal policy, established by the Bush Administration in 2001, allows federal money to be used to support ESR on cell lines created: (1) with appropriate informed consent of the donors; (2) using embryos created for reproductive purposes; and (3) before the date of the policy. The third element has generated the most debate, and prompted some states to fund ESR themselves, and others to further restrict ESR.

Congress has a range of policy options available, each prompting a set of ethical dilemmas. First, it could allow federal funding for ESR regardless of the date the stem cell lines were established, as proposed in H.R. 810 (Castle). The House passed H.R. 810 on May 24, 2005, and the Senate passed the measure on July 18, 2006; President Bush has threatened a veto. Supporters assert that many frozen embryos created for in vitro fertilization (IVF) will be destroyed, and could be used for research regulated by the federal government. Critics seek to limit embryo destruction and federal funding for it. Second, Congress could do nothing, allowing the current policy to endure. Supporters contend the current policy balances research interests and opposition to embryo destruction. Critics for and against ESR call the date delineation ethically irrelevant, either because it stifles research or provides a monopoly to those who first destroyed embryos.

Third, Congress could fund research that may eventually generate embryonic stem cells without destroying embryos. This was proposed in H.R. 3144; S. 1557; S. 2754; and H.R. 5526. Supporters assert this facilitates research without ethical dilemmas. Critics characterize it as unnecessary, costly, and a diversion from developing treatments. Finally, Congress could restrict ESR by banning acts such as certain cloning techniques. While ESR would not be restricted by some proposed cloning bans (S. 876; H.R. 1822; S. 1520), those proposed in H.R. 1357 (Weldon)/S. 658 (Brownback) would curtail some forms of ESR, and would ban the importation of any product derived by banned methods. In the 107th and 108th Congresses, a similar bill passed the House and stalled in the Senate. Supporters claim this approach is respectful of human dignity. Critics claim it is detrimental to many people already living.

This report, which will be updated, is one of several Congressional Research Service (CRS) reports on stem cell research, and details the ethical arguments that surround ESR. The broadest is the balance of embryo destruction and relief of human suffering. More subtle issues focus on the relative importance of the viability of embryos, the purpose of embryo creation, new versus existing cell lines, the consent of donors, the ethics of egg procurement, the effectiveness of alternatives, the possibility of generating embryonic stem cells without destroying human embryos, and the use of federal funding.
# Contents

Introduction ...................................................... 1

Discussion of Ethical Issues ................................. 5
   Embryo Destruction and Relief of Human Suffering .. 5
   Viability of Embryos ......................................... 6
Purpose of Embryo Creation ................................... 7
New and Existing Cell Lines .................................. 8
Consent of Donors ............................................. 9
   Egg Procurement ............................................. 10
Effectiveness of Alternatives ................................. 12
   Generating Embryonic Stem Cells
      Without Destroying Human Embryos ................. 13
Use of Federal Funding ........................................ 14
Stem Cell Research: Ethical Issues

Introduction

Stem cell research is controversial not because of its goals, but rather because of the means of obtaining some of the cells. Research involving most types of stem cells, such as those derived from adult tissues and umbilical cord blood, is uncontroversial, except when its effectiveness as an alternative to embryonic stem cells is debated. The crux of the debate centers around embryonic stem cells, which enable research that may facilitate the development of medical treatments and cures, but which require the destruction of an embryo to derive.1 In addition, because cloning is one method of producing embryos for research, the ethical issues surrounding cloning are also relevant.

Two policies are currently in force governing embryonic stem cell research (ESR). Since FY1996, the Dickey amendment, a provision added to each year’s Labor-Health and Human Services (HHS)-Education appropriations legislation, has prohibited the use of National Institutes of Health funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed. This policy effectively precludes the use of federal funding to derive stem cells from embryos, which typically are produced via in vitro fertilization (IVF). The extracted stem cells are used to generate embryonic stem cell lines that may continue to divide for many months to years. In August 2001, President Bush announced that federal funds could be used for research on human embryonic stem cells, but only on 22 existing stem cell lines.2 Many supporters of ESR view these policies as too restrictive, pointing out that the United States is lagging behind other countries in publishing ESR studies.3 In response, many states are moving forward with their own initiatives to encourage or provide funding for stem cell research (in some cases, therapeutic cloning as well) in order to remain competitive and prevent the relocation of scientists and biotechnology firms to other states or overseas.4

Instead of focusing on the policy’s restrictions, many opponents of ESR caution that spending any federal money to support the research is unethical. Some point to

---


2 For further information, see CRS Report RL33540, *Stem Cell Research: Federal Research Funding and Oversight*, by Judith A. Johnson and Erin Williams.


the actions of South Korean scientist Dr. Hwang Woo Suk, whose laboratory fabricated results of stem cells extracted from cloned embryos, as reflective of a research community “more than willing to play fast and loose with the facts in order to get their way.” Many of those in favor of ESR assert that regulation is desirable in order to ensure that the benefits of the research are affordable by all, that they do not endanger the well-being of women who provide eggs for research, and that they are not used for socially and ethically unacceptable purposes such as eugenics.

In the embryonic stem cell debate, the Bush Administration, a group of Representatives, a group of Senators, and a group of Nobel Laureates have each presented their respective positions on ESR. In addition, various other organizations, individuals, and councils have issued opinions and reports on the topic. Some groups, such as the Christian Legal Society, Focus on the Family, and the Christian Coalition support the 2001 Bush policy. Others, such as the National Academies, the Coalition for the Advancement of Medical Research (CAMR), former First Lady Nancy Reagan, former Presidents Gerald Ford, Jimmy Carter, and Bill

---


7 The Christian Legal Society is a “national grassroots network of lawyers and law students, committed to ... advocating biblical conflict reconciliation, public justice, religious freedom and the sanctity of human life.” At [http://www.clsnet.org/clsPages/vision.php], visited July 15, 2005.

8 Focus on the Family was founded in 1977 by Dr. James Dobson to promote the teachings of Jesus Christ. See [http://www.family.org].

9 The Christian Coalition is “the largest and most active conservative grassroots political organization in America,” at [http://www.cc.org].

10 The National Academies brings together “committees of experts in all areas of scientific and technological endeavor” as “advisors to the Nation.” For statements on ESR and cloning, see National Research Council, Institute of Medicine, National Academies, Stem Cells and the Future of Regenerative Medicine (Washington: National Academies, 2001); and Committee on Science, Engineering and Public Policy and Global Affairs Division et al., Scientific and Medical Aspects of Human Reproductive Cloning (Washington National Academy Press, 2002) at [http://www.nationalacademies.org/about/#org].


Clinton, and the Union of Orthodox Jewish Congregations of America (UOJCA), favor more ESR than the Bush policy allows. Still others, such as the National Right to Life Committee and the United States Conference of Catholic Bishops, oppose all ESR.

Two presidential bioethics advisory panels have considered the issues involved in ESR. The President’s Council on Bioethics (President’s Council) published one report directly on the topic, Monitoring Stem Cell Research, in which it sought to characterize the issues. While the Council made no recommendations there, in two other reports it has recommended that “Congress should ... prohibit the use of human embryos in research beyond a designated stage in their development (between 10 and 14 days after fertilization),” and unanimously recommended “a ban on cloning-to-produce-children,” with a 10-member majority also favoring “a four-year moratorium on cloning-for-biomedical-research,” and a seven-member minority favoring “regulation of the use of cloned embryos for biomedical research.” More
recently, the President’s Council published *Alternative Sources of Human Pluripotent Stem Cells*, a white paper exploring the ethics of four proposals to attempt to generate human embryonic stem cells “without creating, destroying, or harming human embryos.”21 A predecessor to the President’s Council, the National Bioethics Advisory Committee (NBAC),22 recommended federal funding for stem cell research using “embryos remaining after infertility treatments,” but not for the “derivation or use of embryos ... made for research purposes.”23

A number of bills have been proposed in Congress.24 On May 24, 2005, the House passed H.R. 810 (Castle), which would allow federal support of research that utilizes human embryonic stem cells regardless of the date on which the stem cells were derived from a human embryo, thus negating the August 2001 Bush stem cell policy limitation. In July 2005, Senate Majority Leader Bill Frist announced his support for H.R. 810/S. 471 (Specter), and on July 18, 2006, the Senate passed H.R. 810 on a 63-37 vote. President Bush has threatened a veto. The Weldon bill, which passed the House in the 107th and 108th and stalled in the Senate, was reintroduced in the 109th Congress as H.R. 1357 and S. 658 (Brownback). The bill bans the process of cloning as well as the importation of any product derived from an embryo created via cloning. It bans not only reproductive applications, but also research on therapeutic uses, which has implications for stem cell research. Advocates of the legislative ban say that allowing any form of human cloning research to proceed raises serious ethical issues, and will inevitably lead to the birth of a baby that is a human clone. Critics argue that the measure would curtail medical research and prevent Americans from receiving lifesaving treatments created overseas. S. 876; H.R. 1822; and S. 1520 ban only human reproductive cloning. Bills focused on alternative sources of stem cells (H.R. 3144; S. 1557; S. 2754; and H.R. 5526) and on the separate issue of fetal tissue (S. 3504) have also been introduced. In December 2005, the President signed H.R. 2520 (P.L. 109-129), which provides for the collection and maintenance of human cord blood stem cells for the treatment of patients and for research.

---

20 (...continued)


Detailed review of the assorted reports and statements reveals that while positions on ESR may be broadly categorized as for or against, there is an array of finer distinctions present. These finer distinctions, in turn, reveal the variation in ethical and moral as well as factual beliefs. The following discussion breaks down the arguments about ESR according to these finer distinctions, demonstrating both the complexity of the issues and the points of resonance among the groups.

## Discussion of Ethical Issues

### Embryo Destruction and Relief of Human Suffering

Most positions on ESR rest at least in part on the relative moral weight accorded to embryos and that accorded to the prospect of saving, prolonging, or improving others’ lives. For some, the inquiry begins and ends with this question. For instance, one opponent of the research, the American Life League, posits that “human life begins at conception/fertilization and that there is never an acceptable reason for intentionally taking an innocent human life.”

Similarly, the United States Conference of Catholic Bishops states that the research is immoral because it “relies on the destruction of some defenseless human beings for the possible benefit to others.” None of the bills currently proposed would completely prohibit funding for ESR or make the practice illegal. Two companion bills (H.R. 1357 and S. 658) could curtail some ESR by banning human cloning techniques, including those used solely for research purposes. The Dickey amendment, a provision added to each year’s Labor-HHS-Education appropriations legislation since FY1996, has prohibited the use of National Institutes of Health funds for research on embryos. Like the Dickey amendment, H.R. 3144, S. 2754, and S. 1557 would prohibit research on embryos.

Some groups explore the moral standing of human embryos, and also consider the “duty to relieve the pain and suffering of others.” Others take the position that embryos do not have the same moral status as persons. They acknowledge that embryos are genetically human, but hold that they do not have the same moral relevance because they lack specific capacities, including consciousness, reasoning, and sentience. They also argue that viewing embryos as persons would “rule out all fertility treatments that involve the creation and discarding of excess embryos,” and further assert that we do not have the same “moral or religious” response to the

---


natural loss of embryos (through miscarriage) that we do to the death of infants.\textsuperscript{29} Some have also rooted their arguments in religious texts, which inform them that an “isolated fertilized egg does not enjoy the full status of person-hood and its attendant protections.”\textsuperscript{30} They conclude that performing research to benefit persons justifies the destruction of embryos. Acceptance of the notion that the destruction of embryos can be justified in some circumstances forms the basis of pro-stem cell research opinions, and is usually modified with some combination of the distinctions and limitations that follow. None of the proposed bills would end the Dickey Amendment’s ban on the use of federal funds for research involving the destruction of human embryos. H.R. 810 and S. 471 would expand the group of stem cell lines eligible for federal funding by removing the date restriction imposed by President Bush.

**Viability of Embryos**

Some proponents of ESR base their support on the question of whether an embryo is viable. The relevance of the viability distinction rests on the premise that it is morally preferable for embryos that will not grow or develop beyond a certain stage and/or those that would otherwise be discarded to be used for the purpose of alleviating human suffering.

The 2001 Bush policy requires, among other things, use of stem cells derived from only excess (non-viable) embryos for federally funded research. One report of the President’s Council explores the moral significance of viability that is based upon “human choices” rather than an embryo’s “own intrinsic nature,” but draws no conclusions.\textsuperscript{31} A second report broaches the subject of viability, recommending that Congress ban both the transfer of a human embryo to a woman’s uterus for any purpose other than to produce a live-born child, and also research conducted on embryos more than 10 to 14 days after fertilization.\textsuperscript{32} The NBAC report touches on the moral status of embryos in utero and those in vitro,\textsuperscript{33} though NBAC does not specify whether viability was a key rationale for its recommendations. A group of Representatives, a group of Senators,\textsuperscript{34} and CAMR imply but do not state a distinction based on viability by expressly calling for the use of “excess” embryos


\textsuperscript{30} UOJCA letter.


\textsuperscript{33} National Bioethics Advisory Commission, *Ethical Issues in Human Stem Cell Research*, vol. 1, September 1999, p. 50.

\textsuperscript{34} Letter from 58 Senators to President George W. Bush, June 7, 2004, at [http://feinstein.senate.gov/04Releases/r-stemcell-ltr.pdf]. (Hereafter cited as Letter from 58 Senators.)
developed for IVF, and making no mention of those in utero. UOJCA makes a similar argument in its letter. By contrast, the National Academies and the group of Nobel Laureates more broadly support research on embryos, making no mention of viability. H.R. 810 and S. 471 imply a distinction based on viability, proposing that federal funding be available only for ESR on lines derived from excess embryos. S. 876; H.R. 1822; and S. 1520 also imply such a distinction by proposing a prohibition on implanting the product of nuclear transplantation into a uterus or the functional equivalent of a uterus, thereby ensuring that it remains non-viable.

**Purpose of Embryo Creation**

A separate distinction that often leads to the same conclusions as viability is the purpose for which embryos are created. This distinction draws an ethical line based upon the intent of the people creating embryos. In the view of some, it is permissible to create an embryo for reproductive purposes (such as IVF), but impermissible to create one with the intention of destroying it for research. Others worry that moral lines will erode quickly — from using only “spare” embryos left over in fertility clinics to creating human embryos solely for research to creating (or trying to create) cloned embryos solely for research.

Most groups at least note the potential ethical significance of reproductive versus research motives for creating embryos. The 2001 Bush policy draws a motive distinction by including a requirement that federally funded research be conducted only on embryonic stem cell lines derived from embryos created solely for reproductive purposes. NBAC draws the same distinction by recommending that federal funding be used for embryos remaining after infertility treatment but not for research involving the derivation or use of stem cells from embryos made for research purposes or from cloned embryos produced by somatic cell nuclear transfer (SCNT). UOJCA argue similarly that they “believe it is entirely appropriate to utilize for this research existing embryos, such as those created for IVF purposes that would otherwise be discarded but for this research. We think it another matter to create embryos ab initio for the sole purpose of conducting this form of research.”

The President’s Council recommends that Congress ban attempts at conception by any means other than the union of egg and sperm (essentially banning cloning via

---


37 National Bioethics Advisory Commission, *Ethical Issues in Human Stem Cell Research*, vol. 1, September 1999, pp. 70-72. In SCNT the nucleus of an egg is removed and replaced by the nucleus from a mature body cell, such as a skin cell obtained from a patient. In 1996, scientists in Scotland used the SCNT procedure to produce Dolly the sheep, the first mammalian clone.

38 UOJCA letter.
SCNT) but does not specify whether embryos might be created in vitro specifically for research purposes.39 Two Council members expressed a dissenting opinion in a medical journal article, arguing that SCNT “resembles a tissue culture” and that the products of SCNT should be available for research.40 A group of Representatives, a group of Senators, and CAMR imply but do not state that embryos should not be created for research purposes. They overtly call for the use of “excess” embryos developed for IVF and make no mention of embryos created expressly for research.41 By contrast, the National Academies supports the creation of embryos for research purposes, including via cloning (SCNT), to “ensure that stem cell-based therapies can be broadly applied for many conditions and people [by] overcoming the problem of tissue rejection.”42 Mrs. Nancy Reagan, her supporters, and the group of Nobel Laureates also take this position. H.R. 810 and S. 471 draw a distinction based on the purpose of embryo creation by proposing that federal funding be available only for ESR on lines derived from embryos created for individuals seeking fertility treatments. S. 876; H.R. 1822; and S. 1520 also imply a distinction based upon purpose by proposing a prohibition on the creation of embryos via cloning for reproductive purposes but not for therapeutic ones. H.R. 1357 and S. 658 would prohibit all human cloning, including embryos created for research purposes.

**New and Existing Cell Lines**

A further distinction has been drawn based upon the timing of the creation of embryonic stem cell lines. Here, the premise is that it is unacceptable to induce the destruction of embryos for the creation of new lines. However, in cases in which embryos have already been destroyed and the lines already exist, it is morally preferable to use those lines for research to improve the human condition.

This was one central distinction drawn in the 2001 Bush policy, which limited the use of federal funding to research on lines derived on or before the date of the policy. Supporters of the Bush policy on both sides of the issue favor this distinction as a compromise. It allows research on some embryonic stem cell lines. It deters the future destruction of embryos for research. The President’s Council writes that the Bush policy mixes “prudence” with “principle, in the hope that the two might reinforce (rather than undermine) each other.”43 The Council notes that the policy is supported by what it titles a moralist’s notion of when one may benefit from prior bad acts (referring to embryo destruction): it prevents the government from complying in the commission of or encouraging the act in the future, and it reaffirms

---


41 Letter from 206 Members of the House of Representatives; Letter from 58 Senators.


the principle that the act was wrong.\textsuperscript{44} The same report also contains analyses of the Bush policy that characterize distinction between new and existing cell lines as “arbitrary,” “unsustainable,” and “inconsistent.”\textsuperscript{45} The Council itself takes no position in the report on this or any other issue.

Opponents of the Bush policy on both sides of the issue view the distinction between new and existing stem cell lines with reproach. One side, which includes The National Right to Life Committee and the United States Conference of Catholic Bishops, objects because the distinction validates destruction of embryos, and rewards those who did so first with a monopoly. The other side, which includes the National Academies, a group of Representatives, a group of Senators, Nancy Reagan and her supporters, Gerald Ford, CAMR, and the group of Nobel Laureates, objects because the distinction limits the number of embryonic stem cell lines available for research, particularly since the number of authorized lines are dwindling\textsuperscript{46} and are “contaminated with mouse feeder cells.”\textsuperscript{47} Likewise, though NBAC recognized the distinction between destroying embryos and using ones previously destroyed (e.g., “derivation of [embryonic stem] cells involves destroying the embryos, whereas abortion precedes the donation of fetal tissue and death precedes the donation of whole organs for transplantation”),\textsuperscript{48} it still recommended future development of embryonic stem cell lines. UOJCA also recognizes a distinction between new and existing lines: “research on embryonic stem cells must be conducted under careful guidelines [that] ... relate to where the embryonic stem cells to be researched upon are taken from.”\textsuperscript{49} H.R. 3144; S. 2754; and S. 1557 make a distinction based on timing by proposing a prohibition on funding for research involving stem cells “not otherwise eligible for funding by NIH,” which are those created after the August 2001 Bush Administration deadline.

\section*{Consent of Donors}

There is consensus throughout a wide array of viewpoints about ESR that embryos should only be obtained for research with the consent of their biological donors. This consent requirement necessitates that embryos be taken only with donors’ knowledge, understanding, and uncoerced agreement. The donor consent requirement is consistent with the rules governing human beings’ participation in research, and with individuals’ general legal authority to make decisions regarding embryos they procreate. A potential drawback of the requirement is that it may restrict the number of embryos available for research purposes.

\textsuperscript{41} Ibid.

\textsuperscript{44} Ibid.


\textsuperscript{47} Letter from 206 Members of the House of Representatives; Letter from 58 Senators.

\textsuperscript{48} National Bioethics Advisory Commission, \textit{Ethical Issues in Human Stem Cell Research}, vol. 1, September 1999, p. 49.

\textsuperscript{49} UOJCA letter.
The 2001 Bush policy contains a donor consent requirement. It limits approved stem cell lines to those derived with the informed consent of the donors, and obtained without any financial inducements to the donors. The NBAC, the President’s Council, and the UOJCA also favor donor consent requirements. The National Academies notes the importance of informed consent in its discussion of stem cell research oversight requirements. A group of Representatives and a group of Senators mention and imply their support for donor consent requirements. H.R. 810; S 471; and S. 876; H.R. 1822; S. 1520 would all require the consent of donors. H.R. 3144; H.R. 2574; S. 1557 also contain an implicit consent requirement by prohibiting research on stem cell lines not otherwise eligible for NIH funding. Consent is one NIH funding requirement.

Egg Procurement. The topic of informed consent in egg procurement came to the public’s attention in November 2005 with allegations that some human eggs used in South Korean scientist Dr. Hwang’s laboratory had been obtained under coercive conditions. Informed consent can be undermined when a coercive situation prevents a free choice from being made, or when insufficient information is provided to the person making a decision. The situation alleged in Dr. Hwang’s laboratory raises the issue of coercion both because subordinate women in the laboratory allegedly donated eggs, and because some women were allegedly paid for their eggs. A 2002 study conducted by a University of Pennsylvania student raised the issue of insufficient information, finding that a number of programs seeking donor eggs for reproductive purposes downplayed the risks involved in egg retrieval. The wide consensus regarding the need for informed consent necessarily implies similar consensus on the need for an information-rich, coercion-free method of obtaining eggs, however there is some disagreement on the specifics of whether payment for eggs necessarily constitutes coercion.

Paying women for their eggs, which has been debated in the context of seeking donor eggs both for reproductive purposes (for example, to enable women who do not produce their own eggs to become pregnant), and for research purposes, is not unheard of in the United States. According to a 2000 study by the American Society of Reproductive Medicine (ASRM), some IVF programs reportedly offered as much as $5,000 for one egg retrieval cycle, though $2,500 appeared to be a more common amount. Offers of much higher amounts ($50,000 - $100,000) have been reported elsewhere. Dr. Huang’s laboratory reportedly made payments of $1,400 to each
woman who donated eggs. Payments are not illegal in the United States, nor were they illegal in South Korea at the time Dr. Huang’s laboratory allegedly made them. The questions are, is payment for egg donation ever acceptable, and if so, what amount is appropriate?

Several arguments have been put forth in favor of payment for egg donation, many focused on donation for reproductive purposes. First, some have argued that payment creates incentives to increase the number of egg donors, thus facilitating research and benefitting infertile couples. Second, some reason that payment for eggs gives women parity with sperm donors, who may be compensated for donating gametes at a lower rate given that they require a much less involved procedure. Third, some allege that fairness dictates that women who donate eggs ought to be able to benefit from their action. Fourth, some claim that pressures created by financial incentives may be no greater than those experienced by women asked to make altruistic egg donations for relatives or friends, and may thus not rise to the level of coercion. These are the types of arguments that led ASRM to recommend in 2000 that sums of up to $5,000 may be appropriate for typical egg donation, while sums of up to $10,000 may possibly be justified if there are particular difficulties a woman must endure to make her donation.

Several arguments have also been put forth against payment for egg donation. First, some voiced fears that payment might lead to the exploitation of women, particularly poor women, and the commodification of reproductive tissues. Second, some have argued that payment for eggs for research purposes might undermine public confidence in endeavors such as human ESR. Arguments such as these have prompted both the National Academies and the President’s Council to recommend that women not be paid for donating their eggs for research purposes. It also led the President’s Council to note that in theory, there is the possibility that eggs could be procured from ovaries harvested from cadavers, which might at least alleviate concerns related to coercion.

It is worth noting that a woman may choose to undergo egg retrieval for her own reproductive purposes, which would effectively take the process of egg procurement out of the research arena and avoids the question of payment entirely. (For example,

---


this could be an option for a woman seeking IVF because her fallopian tubes are blocked). While not making specific recommendations about payment for research-related egg donation, several groups’ recommendations that only embryos left over from IVF procedures be used for stem cell research (noted above in the *Purpose of Embryo Creation* section) effectively takes the process of egg procurement from women out of the research arena. The Bush policy keeps the consent process for egg retrieval separate from donation by funding research only on lines derived from embryos originally created for fertility treatments. The proposals contained in H.R. 810; S. 471; H.R. 3144; H.R. 2574; and S. 1557 would do the same. S. 876; H.R. 1822; and S. 1520 would allow women who donate eggs for research to receive compensation for their time and inconvenience, but would not allow them to be paid any further “valuable consideration” for their donation.

**Effectiveness of Alternatives**

One factual distinction that has been used to support competing ethical viewpoints is the efficacy of alternatives to ESR. The promise of stem cell therapies derived from adult tissue and umbilical cord blood have buttressed opposition to ESR. Alternatives such as those proposed for consideration by the President’s Council are discussed in the next section. Some opponents of the current method of obtaining embryonic stem cells argue that therapies and cures can be developed without the morally undesirable destruction of embryos. However, not all scientists agree that adult stem cells hold as much potential as embryonic stem cells. Most supporters of ESR believe that it is the quickest and, perhaps in some cases, the only path that will yield results. Supporters also stress that embryonic and other stem cell research should be conducted collaboratively, so that they can inform one another. On a related note, some have pointed out that benefits from one alternative to ESR, umbilical cord blood banking, may only be available to families who can afford to pay private companies’ storage fees.

Findings regarding the effectiveness of alternatives to ESR are mixed. The President’s Council notes that there is a “debate about the relative merits of embryonic stem cells and adult stem cells.”59 Focus on the Family cites promising non-embryonic stem cell research: “adult stem cells may be as “flexible” as embryonic ones and equally capable of converting into various cell types for healing the body.”60 By contrast, the National Academies finds that the “best available scientific and medical evidence indicates that research on both embryonic and adult human stem cells will be needed.”61 NBAC finds in its deliberations that “the claim that there are alternatives to using stem cells derived from embryos is not, at the

---


present time, supported scientifically. CAMR supports both embryonic and adult stem cell research, and adds that “many scientists believe and studies show that embryonic stem cells will likely be more effective in curing diseases because they can grow and differentiate into any of the body’s cells and tissues and thus into different organs.” Mrs. Nancy Reagan and her supporters favor expedient approaches including ESR.

Several pieces of legislation support the development of stem cells from sources other than embryos. For each of fiscal years 2004 through 2006, Congress has allocated money in the Consolidated Appropriations Act for the establishment and continuation of a National Cord Blood Stem Cell Bank within the Health Resources and Services Administration. In 2005, Congress passed H.R. 2520 (P.L. 109-129) for the collection and maintenance of human cord blood stem cells for the treatment of patients and for research. H.R. 3144, H.R. 2574, S. 1557, and S. 2754 would authorize funding for research to attempt to generate pluripotent stem cells without involving human embryos.

Generating Embryonic Stem Cells Without Destroying Human Embryos. One possible alternative to ESR as it has typically been conducted, the ability to generate embryonic stem cells without destroying human embryos, was explored by the President’s Council in their 2005 white paper, described in the introductory section of the report. The white paper discusses four potential methods of obtaining embryonic stem cells without having to destroy embryos. Those methods, the scientific and practical merits of which remain far from settled, are (1) extracting cells from organismically dead embryos; (2) non-harmful biopsy of living embryos; (3) bioengineering embryo-like artifacts; and (4) dedifferentiating somatic cells.

In the white paper, the President’s Council examined the ethical acceptability of each method. The first two seek to avoid the destruction of embryos either by developing standards for declaring an embryo “dead” when its cells have stopped dividing or by removing a cell from an embryo without destroying the embryo itself. The other two methods would avoid having to use an embryo altogether, by attempting to obtain embryonic stem cells through the destruction of something that is not an embryo.

---

66 For more information, see CRS Report RL33540, Stem Cell Research: Federal Research Funding and Oversight, by Judith A. Johnson and Erin D. Williams.
The Council concluded that the use of organismically dead embryos raises a number of ethical questions that have yet to be answered. They include whether it is possible to be certain that an embryo is really dead, whether the proposal would put embryos at additional risk, and whether IVF practitioners would be encouraged to create extra embryos. Regarding the use of non-harmful biopsy, the Council found that it would be ethically unacceptable to test in humans because risks should not be imposed on living embryos destined to become children for the sake of getting stem cells for research.

The Council also concluded that bioengineering embryo-like artifacts raises many serious ethical concerns, including whether the artifact would really be a very defective embryo, the ethics of egg procurement, concerns about the use of genetic engineering itself, and the possibility of its use creating a “slippery slope.” Finally, the Council found the proposal to dedifferentiate somatic cells to be ethically acceptable if and when it became scientifically practical, provided that de facto embryos were not created.

Although some Council members expressed their support for efforts to identify means of obtaining human embryonic stem cells for biomedical research that do not involve killing or harming human embryos, not all of the members agreed. Some expressed concern that all four methods would “use financial resources that would be better devoted to proposals that are likely to be more productive.” One member wrote that he did not support publishing the white paper “with the implied endorsement that special efforts be made in the scientific areas described. While some of the suggestions could be explored in a scientific setting, most are high-risk options that only have an outside chance of success and raise their own complex set of ethical questions.”

S. 2754/H.R. 5526 specifies that the Secretary of the Department of Health and Human Services should take the techniques outlined by the President’s Council into account, and fund attempts to generate sources of pluripotent stem therapies that are not derived from human embryos.

**Use of Federal Funding**

Some division over the support for and opposition to ESR focuses on the question of whether the use of federal funding is appropriate. Those who oppose federal funding argue that the government should not be associated with embryo destruction. They point out that embryo destruction violates the “deeply held moral beliefs of some citizens,” and suggest that “funding alternative research is morally preferable.” Proponents of federal funding argue that it is immoral to discourage life-saving research by withholding federal funding. They point out that consensus support is not required for many federal spending policies, as it “does not violate

---


68 Ibid.
They argue that the efforts of both federally supported and privately supported researchers are necessary to keep the United States at the forefront of what they believe is a very important, cutting edge area of science. Furthermore, supporters believe that the oversight that comes with federal dollars will result in better and more ethically controlled research in the field.

Groups’ positions on federal funding tend to mirror their positions on stem cell research generally. The Bush policy authorizes federal funding for some ESR. The President’s Council does not take a position on the issue, but notes the pros and cons and stresses that there is a “difference between prohibiting embryo research and refraining from funding it.” Focus on the Family generally supports President Bush and his policy, but is “disappointed by his decision to allow federal funding of research on the existing stem cell lines.” NBAC finds the arguments in favor of federal funding more persuasive than those against it. The National Academies, a group of Representatives, a group of Senators, Mrs. Nancy Reagan and her supporters, CAMR, the Nobel Laureates, and the UOJCA favor federal funding for ESR.

Several pieces of legislation would use federal funding to add ethical requirements to the conduct of ESR. While the Bush policy did contain some ethical requirements for research on the lines to be funded, it only provided funding for ESR with existing lines. Research conducted before the policy could not have been influenced by its ethical constraints; and research conducted afterwards was not eligible for funding, and was thus not bound by the constraints. The same is true for H.R. 3144; S. 2754; S. 1557 in that they prohibit funding for ESR not otherwise eligible for funding at NIH, which has been set by the Bush policy. H.R. 810; S. 471 would require ESR to be conducted with informed consent and only on excess embryos generated from fertility treatments. S. 876; H.R. 1822; S. 1520 would fund ESR and require that it be conducted with informed consent, after examination by an Institutional Review Board, and with certain privacy and security provisions, and that embryos not be maintained for more than 14 days from initial cell division, to prevent reproductive human cloning.

---

69 Ibid.